276 related articles for article (PubMed ID: 23643255)
1. Migraine, triptans, and the risk of developing rosacea: a population-based study within the United Kingdom.
Spoendlin J; Voegel JJ; Jick SS; Meier CR
J Am Acad Dermatol; 2013 Sep; 69(3):399-406. PubMed ID: 23643255
[TBL] [Abstract][Full Text] [Related]
2. The risk of newly diagnosed asthma in migraineurs with or without previous triptan prescriptions.
Becker C; Brobert GP; Almqvist PM; Johansson S; Jick SS; Meier CR
Headache; 2008 Apr; 48(4):606-10. PubMed ID: 18194300
[TBL] [Abstract][Full Text] [Related]
3. Prevalence and risk of migraine in patients with rosacea: A population-based cohort study.
Egeberg A; Ashina M; Gaist D; Gislason GH; Thyssen JP
J Am Acad Dermatol; 2017 Mar; 76(3):454-458. PubMed ID: 27817869
[TBL] [Abstract][Full Text] [Related]
4. Rates and predictors of starting a triptan: results from the American Migraine Prevalence and Prevention Study.
Bigal ME; Buse DC; Chen YT; Golden W; Serrano D; Chu MK; Lipton RB
Headache; 2010 Oct; 50(9):1440-8. PubMed ID: 20533956
[TBL] [Abstract][Full Text] [Related]
5. Patterns of use and health expenses associated with triptans among adults with migraines.
Wu J; Noxon V; Lu ZK
Clin J Pain; 2015 Aug; 31(8):673-9. PubMed ID: 25185875
[TBL] [Abstract][Full Text] [Related]
6. Migraine incidence, comorbidity and health resource utilization in the UK.
Becker C; Brobert GP; Almqvist PM; Johansson S; Jick SS; Meier CR
Cephalalgia; 2008 Jan; 28(1):57-64. PubMed ID: 17986274
[TBL] [Abstract][Full Text] [Related]
7. Risk of Acute Myocardial Infarction, Heart Failure, and Death in Migraine Patients Treated with Triptans.
Ghanshani S; Chen C; Lin B; Duan L; Shen YA; Lee MS
Headache; 2020 Nov; 60(10):2166-2175. PubMed ID: 33017476
[TBL] [Abstract][Full Text] [Related]
8. Factors associated with triptan use in episodic migraine: results from the American Migraine Prevalence and Prevention Study.
Chu MK; Buse DC; Bigal ME; Serrano D; Lipton RB
Headache; 2012 Feb; 52(2):213-23. PubMed ID: 22413150
[TBL] [Abstract][Full Text] [Related]
9. Adding Additional Acute Medications to a Triptan Regimen for Migraine and Observed Changes in Headache-Related Disability: Results From the American Migraine Prevalence and Prevention (AMPP) Study.
Buse DC; Serrano D; Reed ML; Kori SH; Cunanan CM; Adams AM; Lipton RB
Headache; 2015 Jun; 55(6):825-39. PubMed ID: 25881857
[TBL] [Abstract][Full Text] [Related]
10. A study on the epidemiology of rosacea in the U.K.
Spoendlin J; Voegel JJ; Jick SS; Meier CR
Br J Dermatol; 2012 Sep; 167(3):598-605. PubMed ID: 22564022
[TBL] [Abstract][Full Text] [Related]
11. Adverse cardiovascular events associated with triptans and ergotamines for treatment of migraine: systematic review of observational studies.
Roberto G; Raschi E; Piccinni C; Conti V; Vignatelli L; D'Alessandro R; De Ponti F; Poluzzi E
Cephalalgia; 2015 Feb; 35(2):118-31. PubMed ID: 25246519
[TBL] [Abstract][Full Text] [Related]
12. Triptans and vascular comorbidity in persons over fifty: Findings from a nationwide insurance database - A cohort study.
Zebenholzer K; Gall W; Gleiss A; Pavelic AR; Wöber C
Headache; 2022 May; 62(5):604-612. PubMed ID: 35593784
[TBL] [Abstract][Full Text] [Related]
13. Potential Channeling Bias in the Evaluation of Cardiovascular Risk: The Importance of Comparator Selection in Observational Research.
Li H; Mawanda F; Mitchell L; Zhang X; Goodloe R; Vincent M; Motsko S
Pharmaceut Med; 2022 Aug; 36(4):247-259. PubMed ID: 35788962
[TBL] [Abstract][Full Text] [Related]
14. Migraine and the risk of stroke, TIA, or death in the UK (CME).
Becker C; Brobert GP; Almqvist PM; Johansson S; Jick SS; Meier CR
Headache; 2007; 47(10):1374-84. PubMed ID: 18052947
[TBL] [Abstract][Full Text] [Related]
15. Antihypertensive drugs and the risk of incident rosacea.
Spoendlin J; Voegel JJ; Jick SS; Meier CR
Br J Dermatol; 2014 Jul; 171(1):130-6. PubMed ID: 24428524
[TBL] [Abstract][Full Text] [Related]
16. Triptan use and risk of cardiovascular events: a nested-case-control study from the French health system database.
Lugardon S; Roussel H; Sciortino V; Montastruc JL; Lapeyre-Mestre M
Eur J Clin Pharmacol; 2007 Aug; 63(8):801-7. PubMed ID: 17576547
[TBL] [Abstract][Full Text] [Related]
17. Rates and reasons for discontinuation of triptans and opioids in episodic migraine: results from the American Migraine Prevalence and Prevention (AMPP) study.
Holland S; Fanning KM; Serrano D; Buse DC; Reed ML; Lipton RB
J Neurol Sci; 2013 Mar; 326(1-2):10-7. PubMed ID: 23394974
[TBL] [Abstract][Full Text] [Related]
18. Effects of switching acute treatment on disability in migraine patients using triptans.
Serrano D; Buse DC; Kori SH; Papapetropoulos S; Cunanan CM; Manack AN; Reed ML; Lipton RB
Headache; 2013 Oct; 53(9):1415-29. PubMed ID: 23808937
[TBL] [Abstract][Full Text] [Related]
19. Triptan use as a function of cardiovascular risk. A population-based study.
Bigal ME; Golden W; Buse D; Chen YT; Lipton RB
Headache; 2010 Feb; 50(2):256-63. PubMed ID: 20039953
[TBL] [Abstract][Full Text] [Related]
20. Migraine treatment strategies: the global Migraine And Zolmitriptan Evaluation (MAZE) survey--phase IV.
MacGregor EA; Brandes J; Gendolla A; Giammarco R
Curr Med Res Opin; 2004 Nov; 20(11):1777-83. PubMed ID: 15537478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
